Assyro AI

Orange Book product · Brand (NDA)

RYALTRIS

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

Brand (NDA)NDA 211746RX GLENMARK SPECLT
View MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE familyOpen on FDA Orange Book

At a glance

Jan 13, 2022

Approved

Brand (NDA)

Application

Not listed

TE code

16

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jan 13, 2022

    4 yr 6 mo ago

  2. Today

  3. Patent 10016443 expires

    Listed method-of-use patent (U-3297) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  4. Patent 10376526 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  5. Patent 10517880 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  6. Patent 10548907 expires

    Listed method-of-use patent (U-3297) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  7. Patent 10561672 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  8. Patent 10646500 expires

    Listed method-of-use patent (U-3297) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  9. Patent 10758550 expires

    Listed method-of-use patent (U-3296) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  10. Patent 10765686 expires

    Listed method-of-use patent (U-3295) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  11. Patent 11400101 expires

    Listed method-of-use patent (U-3297) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  12. Patent 12064442 expires

    Listed method-of-use patent (U-3297) expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  13. Patent 9078923 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  14. Patent 9370483 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  15. Patent 9750754 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  16. Patent 9937189 expires

    Listed drug product patent expiration.

    Sep 04, 2034

    in 8 yr 4 mo

  17. Patent 11679210 expires

    Listed drug product patent expiration.

    Sep 03, 2038

    in 12 yr 5 mo

  18. Patent 12303635 expires

    Listed drug substance patent expiration.

    Apr 08, 2039

    in 13 yr

Pharmaceutical detail

Active ingredient

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

Strength

0.025MG/SPRAY;0.665MG/SPRAY

Dosage form

SPRAY, METERED

Route

NASAL

TE code

Not listed

Application

NDA 211746

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (16)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10016443Sep 04, 2034in 8 yr 4 mo
U-3297
10376526Sep 04, 2034in 8 yr 4 mo
Product
10517880Sep 04, 2034in 8 yr 4 mo
ProductU-3297
10548907Sep 04, 2034in 8 yr 4 mo
U-3297
10561672Sep 04, 2034in 8 yr 4 mo
Product
10646500Sep 04, 2034in 8 yr 4 mo
U-3297
10758550Sep 04, 2034in 8 yr 4 mo
U-3296
10765686Sep 04, 2034in 8 yr 4 mo
U-3295
11400101Sep 04, 2034in 8 yr 4 mo
U-3297
12064442Sep 04, 2034in 8 yr 4 mo
U-3297
9078923Sep 04, 2034in 8 yr 4 mo
ProductU-3297
9370483Sep 04, 2034in 8 yr 4 mo
Product
9750754Sep 04, 2034in 8 yr 4 mo
ProductU-3297
9937189Sep 04, 2034in 8 yr 4 mo
Product
11679210Sep 03, 2038in 12 yr 5 mo
Product
12303635Apr 08, 2039in 13 yr
SubstanceProduct
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo